Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280149 | 0.73 | TRPA1 (0.36) | TRPA1RXFP1 | |
| SCHEMBL14275408 | 0.68 | L3MBTL1 (0.34) | — | |
| SCHEMBL7988350 | 0.66 | GAA (0.51) | RXFP1 | |
| SCHEMBL19409223 | 0.65 | ADORA2A (0.36) | — | |
| SCHEMBL19036405 | 0.63 | TRPA1 (0.34) | TRPA1RXFP1 | |
| SCHEMBL10151289 | 0.63 | TRPA1 (0.34) | TRPA1RXFP1 | |
| SCHEMBL21861602 | 0.62 | TRPA1 (0.41) | TRPA1RXFP1 | |
| SCHEMBL19409249 | 0.59 | ALDH1A1 (0.47) | RXFP1 | |
| SCHEMBL15384376 | 0.58 | TRPA1 (0.33) | TRPA1RXFP1 | |
| SCHEMBL21861536 | 0.58 | TRPA1 (0.44) | TRPA1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885RXFP1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.